biostudies-literatureTerzic VAgency for Clinical Research and Biomedical InnovationDomaine d’intérêt majeur One Health Île-de-FranceEuropean Regional Development Fund (Luxembourg)Austrian Group Medical Tumor (Austria)Agency for Clinical Research and Biomedical Innovation (Portugal)Austrian Group Medical TumorMinistry of HealthBelgian Health Care Knowledge CentreMinistry of Health (Portugal)EU's Horizon 2020 Research and Innovation ProgramFonds Erasme-COVID-Université Libre de Bruxelles (Belgium)Belgian Health Care Knowledge Centre (Belgium)Domaine d'intérêt majeur One Health Île-de-France (France)Merck Sharp &amp; Dohme LLCREACTingFonds Erasme-COVID-Université Libre de BruxellesEU&apos;s Horizon 2020 Research and Innovation ProgramGilead Sciences, IncEuropean Regional Development Fund382-391https://www.ebi.ac.uk/biostudies/studies/S-EPMC11327784biostudies-literatureUnknown79(2)<h4>Background</h4>We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with coronavirus disease 2019 (COVID-19) who received remdesivir plus standard of care (SoC) compared with SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases.<h4>Methods</h4>This post hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19. Any first AE that occurred between randomization and day 29 in the modified intention-to-treat (mITT) population randomized to either remdesivir or control group was considered. Analysis was performed using Kaplan-Meier survival curves, and Kaplan-Meier estimates were calculated for event ratesClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaCardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.PMC11327784PHRC 20-0351101015736Billard NThiery GBernard LLefevre BRibeiro JMFOulehri WTacconelli EBurdet CRichard JCBruel CRouveix-Nordon EHinschberger OBelhadi DPiroth LRoncon-Albuquerque RMourvillier BGoehringer FNseir SLe Moing VTextoris JBerna MLamprecht BPaiva JATimsit JFEpelboin LKlouche KHites MTacquard CMayaux JGousseff MRoger CLacombe KDelbove ALeroy SMootien JMarquette CHLe Tulzo YLaviolle BMira JPKimmoun AJaureguiberry SLaine FZerbib YMekontso-Dessap ABani-Sadr FGarot DBenezit FCazanave CFougerou-Leurent CBouchaud OArgaud LFartoukh MFerry TLoubet PLescure FXYazdanpanah YGreil RPourcher VValour FPilmis BGeri GChabartier CWattecamps GLanoix JPBouiller KTerzi NMurris-Espin MGallien SPeiffer-Smadja NCourjon JPerpoint TEgle AGruson DBelkhir LRevest MBraz SStefan FJeanmichel VNavellou JCKerneis SDubost Cde Gastines LChirouze CLeveau BMartin-Blondel GDiallo ABotelho-Nevers ERoger PAAboab JMeziani FJoannidis MBoutoille DFicko CGagneux-Brunon AStaub TTolsma VLessire HBoyer ADelmas CMonnet XAndrejak CDisCoVeRy Study GroupDellamonica JLaunay OAit-Oufella HMalvy DBouadma LMolina JMFraipont VFaure ERaffi FSenneville EDjossou FRobert CAltdorfer AFaure KRiu-Poulenc BEsperou HCabie ADuvignaud ASaidani NGaci RCostagliola DTerzic VCanet EMiantezila Basilua JGaborit BMentre FEpaulard OAder FAndreu PWallet FGibot SMakinson AFigueiredo SCrockett FFerrane ALe Pavec JMartinot MDanion FDechanet AMercier NBougon DTurmel JMSayre NHansmann YReuter JVerschelden GBounes-Vardon FReignier JPialoux GCouffin-Cadiergues SPoissy JLe Turnier PQuenot JPBlot MLachatre MPiriou VSotto ALebeaux DfalseCardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.<h4>Background</h4>We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with coronavirus disease 2019 (COVID-19) who received remdesivir plus standard of care (SoC) compared with SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases.<h4>Methods</h4>This post hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19. Any first AE that occurred between randomization and day 29 in the modified intention-to-treat (mITT) population randomized to either remdesivir or control group was considered. Analysis was performed using Kaplan-Meier survival curves, and Kaplan-Meier estimates were calculated for event rates2024-01-01T00:00:00Z2024 Aug2026-06-03T00:14:25.698Z2024-11-09T15:42:55.574ZS-EPMC113277843855220810.1093/cid/ciae170